BlueRun Ventures Continues to Double Down: Morelly Bio Closes New Nine-Figure RMB Funding Round | BlueRun Portfolio
Delivering more competitive Chinese solutions for the global medical aesthetics market
蓝驰创投
@lanchi
不被定义
371 articles
Articles
They Talk, We Create | Quarterly
The evening breeze of a summer night is the sound of the future rushing in.
On the Eve of AGI: The Last Night on Earth | Booming Night
Twelve Moments from Booming Night
Welcome to Register: 2025 World Robot Conference Project Roadshow and Investment-Matching Session | BlueRun Ventures × Shoucheng Capital
Face to Face with a Robot
Z Hub Tech Enterprise Series × Blueprint Talks — Embodied Intelligence Special Successfully Held: Exploring New Opportunities for Embodied Intelligence Industry Deployment
Deepening the integration of technology, industry, and capital.
A Conversation with Lingchu AI CEO Qibin Wang: On Robotics Technology Roadmap Choices, and the Key Breakthroughs for VLA Capabilities | BlueRun Ventures Family Headlines
Peng! Play Mahjong with a robot!
Only Two in China! Yang Yaodong's Team from the Peking University-Lingchu AI Joint Lab and DeepSeek's Wenfeng Liang Win ACL 2025 Best Paper | BlueRun Ventures Family Headlines
Continuously Challenging the Frontier of Innovation
Partnering with Eli Lilly and Company! Zai Lab's Globally First-in-Class "Myeloid Cell Engager" Platform Opens New Frontiers in Autoimmune Disease Treatment | BlueRun Ventures Family Headlines
Zean Bioscience Charts a New Course for Autoimmune Disease Treatment
A BlueRun Ventures portfolio company delivered a striking glimpse of AI's next evolutionary leap at WAIC.
Evolution, Toward the Future
Kun Jing's Genspark Column Updated Again: Multi-Model and Multi-Agent Are the Future
"The Idea of a Single Super Agent That Does Everything Just Sounds Good"